	US 12,358,908 B2
	Crystals, preparation method and application of a muscarinic receptor antagonist
Xiaoping Chen, Beijing (CN); and Zejun Gao, Beijing (CN)
Assigned to BEIJING SHOWBY PHARMACEUTICAL CO., LTD., (CN)
Appl. No. 17/921,610
Filed by BEIJING SHOWBY PHARMACEUTICAL CO., LTD., Beijing (CN)
PCT Filed Apr. 24, 2021, PCT No. PCT/CN2021/089464 § 371(c)(1), (2) Date Oct. 26, 2022, PCT Pub. No. WO2021/218833, PCT Pub. Date Nov. 4, 2021.
Claims priority of application No. 202010338830.0 (CN), filed on Apr. 26, 2020.
Prior Publication US 2023/0167107 A1, Jun. 1, 2023
Int. Cl. C07D 453/02 (2006.01)

CPC C07D 453/02 (2013.01) [C07B 2200/13 (2013.01)]

18 Claims

1. A Type-A crystal of (2R,3R)-3-[(2-cyclopentyl-2-hydroxy-2-phenyl) ethoxy]-1-(3-phenoxypropyl)-1-azabicyclo[2,2,2]octylonium bromide, displaying diffraction peaks at the following diffraction angles 2θ in an X-ray powder diffraction pattern:

5.7±0.2 degrees, 12.9±0.2 degrees, 16.7±0.2 degrees, 18.0±0.2 degrees, 19.5±0.2 degrees, 21.1±0.2 degrees, 22.3±0.2 degrees, and 23.3±0.2 degrees,

wherein the X-ray powder diffraction pattern is a spectrum obtained by using Cu Kα rays.